PM8002/BNT327 Combo Improves Efficacy and Safety in Metastatic TNBC
Data from a phase 1b/2 study show a 78.6% ORR in patients with metastatic triple-negative breast cancer treated with PM8002/BNT327 plus nab-paclitaxel.
Related Articles
Taletrectinib Displays Efficacy, Tolerability in ROS1+ NSCLC in Multiple Clinical Trials
Investigators hope to add a treatment option that has the potential to produce superior efficacy vs present ROS1 inhibitors for patients with ROS1+ NSCLC.
Aspirin is associated with lower risk of pancreatic cancer and cancer-related mortality in patients with diabetes mellitus
Background Patients with type 2 diabetes mellitus (T2DM) have higher pancreatic cancer (PC) risk. While aspirin has chemopreventive effects on digestive cancers, its effect on…
NRG1 Fusions Emerge as New Target of Interest in Lung, Pancreatic Cancers
NRG1 fusion positivity has gained interest as a treatment target in lung and pancreatic cancer, leading to the FDA approval of zenocutuzumab in December 2024.
Novel CAR T-Cell Therapy Trial Advances to Third Cohort in Ovarian Cancer
A phase 1 trial evaluating FSHR-targeting CAR T cells for patients with ovarian cancer has dosed the first patient in its third cohort.
Fertility Counseling and Preservation in Patients With NHL | Blood Cancers Today
Researchers say barriers such as time constraints and financial limitations complicate fertility counseling and preservation for patients with lymphoma.
Active Monitoring Is Noninferior to Guideline Concordant Care in Low-Risk DCIS
Rates of invasive cancer were noninferior when patients with low-risk ductal carcinoma in situ received active monitoring vs guideline concordant care.
Immune Checkpoint Inhibitors: 10-Year Results in Melanoma Are Now Out – Let’s Reflect on These Impressive Advances.
Remarkable advances and remaining questions.
2024 Most Read Articles | Blood Advances | American Society of Hematology
2024 Most Read Articles | Blood Advances | American Society of Hematology Top Ten Most Read Articles in 2024 Blood Advances is pleased to announce…
Expanding JAK Inhibitor Arsenal Provides Additional Options Beyond Ruxolitinib in Myelofibrosis
Aaron Gerds, MD, discusses differences in molecular targets, efficacy, and toxicity profiles between available JAK inhibitors in myelofibrosis.
Immune Checkpoint Inhibitors: 10-Year Results in Melanoma Are Now Out – Let’s Reflect on These Impressive Advances.
Remarkable advances and remaining questions.